Literature DB >> 23255124

Quality analysis of commercial fish oil preparations.

Jenna C Sullivan Ritter1, Suzanne M Budge, Fabiola Jovica.   

Abstract

BACKGROUND: Fish oil supplements have grown in popularity in recent years owing to their multiple health benefits, leading to rapid growth in the number of fish oil supplements available for consumers. When choosing a product, it is important that label claims for eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are met, especially when a specific dosage is required. In this study the amounts of EPA and DHA in 16 of the top-selling liquid fish oil products from the American marketplace were analysed and compared with their label claims. Peroxide value, a measure of oxidation, was also determined, along with lipid class.
RESULTS: This study found that over half of the supplements did not meet their label claims for EPA and DHA, and a quarter exceeded recommended limits for peroxide value.
CONCLUSION: These results suggest that more stringent regulation is required for fish oil products.
© 2012 Society of Chemical Industry.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23255124     DOI: 10.1002/jsfa.5994

Source DB:  PubMed          Journal:  J Sci Food Agric        ISSN: 0022-5142            Impact factor:   3.638


  14 in total

Review 1.  Controversies in the Use of Omega-3 Fatty Acids to Prevent Atherosclerosis.

Authors:  Renato Quispe; Abdulhamied Alfaddagh; Brigitte Kazzi; Fawzi Zghyer; Francoise A Marvel; Roger S Blumenthal; Garima Sharma; Seth S Martin
Journal:  Curr Atheroscler Rep       Date:  2022-04-30       Impact factor: 5.967

Review 2.  Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA).

Authors:  Eliot A Brinton; R Preston Mason
Journal:  Lipids Health Dis       Date:  2017-01-31       Impact factor: 3.876

3.  Omega-3 Long-Chain Polyunsaturated Fatty Acid Content and Oxidation State of Fish Oil Supplements in New Zealand.

Authors:  Gerard Bannenberg; Craig Mallon; Holly Edwards; Derek Yeadon; Kevin Yan; Holly Johnson; Adam Ismail
Journal:  Sci Rep       Date:  2017-05-03       Impact factor: 4.379

4.  Concerns with the Study on Australian and New Zealand Fish Oil Products by Nichols et al. (Nutrients 2016, 8, 703).

Authors:  Benjamin B Albert; José G B Derraik; Manohar L Garg; David Cameron-Smith; Wayne S Cutfield
Journal:  Nutrients       Date:  2017-02-14       Impact factor: 5.717

Review 5.  New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease.

Authors:  R Preston Mason
Journal:  Curr Atheroscler Rep       Date:  2019-01-12       Impact factor: 5.113

Review 6.  Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review.

Authors:  Daniel E Hilleman; Barbara S Wiggins; Michael B Bottorff
Journal:  Adv Ther       Date:  2020-01-09       Impact factor: 3.845

Review 7.  Prescription omega-3 fatty acid products: considerations for patients with diabetes mellitus.

Authors:  Nadeem Tajuddin; Ali Shaikh; Amir Hassan
Journal:  Diabetes Metab Syndr Obes       Date:  2016-04-19       Impact factor: 3.168

8.  Switching statin-treated patients from fenofibrate to the prescription omega-3 therapy icosapent ethyl: a retrospective case series.

Authors:  Richard S Castaldo
Journal:  Drugs Ther Perspect       Date:  2016-03-08

Review 9.  Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products.

Authors:  Jonathan Fialkow
Journal:  Am J Cardiovasc Drugs       Date:  2016-08       Impact factor: 3.571

Review 10.  Are dietary fish oil supplements appropriate for dyslipidemia management? A review of the evidence.

Authors:  Samuel C R Sherratt; Michael Lero; R Preston Mason
Journal:  Curr Opin Lipidol       Date:  2020-04       Impact factor: 4.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.